Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

The Cubs had the chance to cement themselves as National League contenders this offseason. The post Cubs’ Alex Bregman Regret ...

Hinge Health, which provides digital exercise therapy programs to help people manage and overcome muscle and joint pain, on ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

The Boston Red Sox had a fantastic offseason. The last few offseasons were pretty slow for Boston but this past one was ...

Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...

The Soldotna boys finished with a win, while the Soldotna girls finished with two losses, Saturday at the Northern Lights ...

LONGVIEW: The Lobos split a pair of games on Friday at the Hallsville Tournament, and closed out the event with a loss to the ...

MESA—In a matchup of the top two teams in the Cactus League, the Chicago Cubs squared off against the San Francisco Giants ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.